CagriSema

CagriSema is a once-weekly fixed-dose combination of cagrilintide 2.4 mg (a long-acting amylin analogue) and semaglutide 2.4 mg (the GLP-1 receptor agonist in Wegovy and Ozempic) in a single subcutaneous injection. Novo Nordisk submitted the New Drug Application to the FDA on December 18, 2025 — the first GLP-1 + amylin combination ever submitted for regulatory approval. In the pivotal REDEFINE 1 Phase 3 trial it produced 22.7% mean weight loss at 68 weeks, versus 16.0% for semaglutide alone. FDA decision is expected approximately October 2026.

Novo Nordisk filed the NDA on December 18, 2025. Based on the standard 10-month FDA review clock, a decision is expected approximately October 2026. No PDUFA target date has been publicly confirmed. If approved, commercial launch would likely follow shortly after decision. No other country has issued an approval or accepted a submission as of April 2026.

In REDEFINE 1, the direct head-to-head comparison, CagriSema produced 22.7% weight loss versus 16.0% for semaglutide 2.4 mg alone at 68 weeks — a roughly 40% relative improvement over semaglutide monotherapy at the same semaglutide dose. 60% of CagriSema patients achieved ≥20% weight loss, compared to a minority on semaglutide alone. The mechanism is additive, not redundant: adding cagrilintide engages amylin receptors in the area postrema, a satiety pathway that GLP-1 doesn't reach.

No direct head-to-head trial exists. Cross-trial comparison (different populations, different trial designs — caveat that limitation): CagriSema produced 22.7% weight loss in REDEFINE 1 at 68 weeks; tirzepatide 15 mg produced 20.9% at 72 weeks in SURMOUNT-1 (also non-diabetic). The effects are approximately comparable in obesity. Tirzepatide is FDA-approved and commercially available as Zepbound today; CagriSema is not yet approved. Mechanistically, both combine two weight-loss pathways, but tirzepatide does so as a single molecule (GLP-1 + GIP dual agonist) while CagriSema does so as a fixed-dose combination of two molecules (GLP-1 + amylin).

REDEFINE 1 (Garvey et al., NEJM 2025) was the pivotal Phase 3 trial supporting the CagriSema NDA. 3,417 adults without diabetes and with a BMI ≥30 (or ≥27 with at least one obesity-related complication) were randomized 21:3:3:7 to CagriSema 2.4/2.4 mg, semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone, or placebo, for 68 weeks plus lifestyle intervention. Primary endpoint: relative body weight change and proportion achieving ≥5% loss. CagriSema produced 22.7% weight loss (trial-product estimand) or 20.4% (treatment-policy estimand), both highly statistically significant versus placebo.

Cagrilintide is a long-acting amylin analogue — technically a DACRA, meaning it activates both amylin and calcitonin receptors. Amylin is a hormone co-secreted with insulin from pancreatic β-cells; its primary action is at the area postrema in the hindbrain, where it reduces food intake, enhances satiety, and may restore leptin sensitivity. This is a fundamentally different pathway from GLP-1, which works primarily through hypothalamic circuits. Cagrilintide on its own produced 11.8% weight loss in REDEFINE 1. Combining it with semaglutide stacks two non-overlapping satiety systems, which is why the combination exceeds either component alone.

The side-effect profile is dominated by GI effects characteristic of both GLP-1 and amylin agonism: nausea (most common, peaks during titration), vomiting (~25–30%), diarrhea (~25%), constipation (~20%), and abdominal pain (~15%). Gastrointestinal adverse events occurred in ~80% of CagriSema patients versus ~40% of placebo in REDEFINE 1, and GI burden is modestly higher than with semaglutide alone. Injection-site reactions were more frequent than with semaglutide alone, attributed to the cagrilintide component. Most AEs were transient and mild-to-moderate, with a permanent discontinuation rate modestly higher than for semaglutide monotherapy.

Yes, but less powerfully than in non-diabetic populations. REDEFINE 2 (Davies et al., NEJM 2025) enrolled adults with T2DM and overweight/obesity and produced 15.7% weight loss at 68 weeks — meaningful, but smaller than the 22.7% in REDEFINE 1's non-diabetic cohort. This blunting of GLP-1-class weight-loss response in diabetes is well-documented and not unique to CagriSema. Glycemic improvements were substantial, and hypoglycemia incidence was low. The NDA package includes REDEFINE 2, so if approved, diabetic patients with obesity would likely be in the label.

Not lawfully for human use. CagriSema is investigational and available only through Novo Nordisk's REDEFINE clinical trials. Compounding pharmacies cannot lawfully compound CagriSema because the fixed-dose combination has no reference listed drug and is not on the FDA Drug Shortage list — this is different from the compounded semaglutide situation, where active shortages opened a compounding pathway. Some peptide vendors sell 'research use only' cagrilintide separately, but these products are not FDA-regulated, have variable purity, and are not legal to administer to humans. Waiting for approval (expected October 2026) is the only safe path.

Development timelines for combination products are usually longer than for single-agent drugs because each component needs its own evidence base before a fixed-dose formulation can be submitted. Cagrilintide's Phase 2 monotherapy dose-finding (Lau 2021) and the Phase 1b combination safety study (Enebo 2021) ran in parallel with semaglutide's own late-stage development. The first CagriSema Phase 2 in T2DM (Frías 2023) established dose selection, then the REDEFINE Phase 3 program ran from 2022 through 2024 with publication of REDEFINE 1 and 2 in mid-2025 and NDA submission in December 2025. Fast by pharma standards — roughly four years from first combination Phase 2 readout to NDA filing.